Buenos Aires Breast Cancer Symposium 2024: Bridging basic and clinical research in breast cancer Editorial
| Authors: | Abba, M.; Behbod, F.; Ceppi, P.; Chammas, R.; Clarke, R.; Dalotto, T.; De Siervi, A.; Abuin, G. G.; Gottifredi, V.; Hoadley, K. A.; Jerry, J.; Juric, D.; Kordon, E.; Lanari, C.; Lee, A.; Mahmoud, Y. D.; Mandó, P.; Maurer, J.; Mauro, F.; Miller, T.; Muller, W. J.; Novaro, V.; Oesterreich, S.; Park, C.; Pettit, S.; Razavi, P.; Richer, J.; Roqué, M.; Rossi, M.; Salaberry, P. J.; Salatino, M.; Sciacca, M.; Vallone, S. A.; Vilarullo, R. N.; Vivanco, M.; Waisberg, F.; Welm, A.; Wolos, V. J. |
| Title: | Buenos Aires Breast Cancer Symposium 2024: Bridging basic and clinical research in breast cancer |
| Abstract: | The second edition of the Buenos Aires Breast Cancer Symposium (BA-BCS), the first to be held in person, took place from September 3rd to 6th, 2024, in Buenos Aires, Argentina. Nineteen scientists from Brazil, Canada, the United States, the United King-dom, Denmark, Germany, and Spain, along with six Argentine experts, shared and discussed their recent findings with the audience. Young researchers had the opportunity to present their results through either mini-oral presentations or posters, facilitating one-on-one interactions and the potential for new colla-borations. This article summarizes each talk presented at the symposium. © 2025, Fundacion Revista Medicina (Buenos Aires). All rights reserved. |
| Keywords: | protein expression; unclassified drug; somatic mutation; cancer recurrence; cancer risk; drug efficacy; drug potentiation; monotherapy; nonhuman; united states; bone metastasis; drug targeting; paclitaxel; antineoplastic agent; sensitivity and specificity; polymerase chain reaction; dna damage; dna repair; chemoprophylaxis; metastasis; quality of life; biomedical research; congresses as topic; ovary cancer; breast cancer; microrna; gene expression; mastectomy; tumor differentiation; aromatase inhibitor; tumor xenograft; drug resistance; drug specificity; breast neoplasms; transcriptomics; carcinogenesis; cancer hormone therapy; oncogene; tumor suppressor gene; patient care; lung metastasis; regulatory t lymphocyte; medical research; breast tumor; drug response; cancer stem cell; tumor cell; cell migration; clinical research; organization; tamoxifen; tumor immunity; chromosomal instability; nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor; double stranded dna break; tumor promotion; argentina; tumor growth; progesterone receptor; trastuzumab; risk reduction; estradiol; cyclin dependent kinase inhibitor; cell interaction; breast surgery; oxidative phosphorylation; therapy; drug protein binding; protein inhibitor; antiestrogen; osteoclast differentiation factor; butyric acid; fulvestrant; olaparib; tumor necrosis factor; translational research; cyclin dependent kinase 1; phosphatidylinositol 3 kinase inhibitor; non small cell lung cancer; tumor microenvironment; protein kinase b inhibitor; mucin 4; antiproliferative activity; symposium; triple negative breast cancer; adipocyte; epithelial mesenchymal transition; bone marrow metastasis; estrogen receptor alpha; germline mutation; transcription factor runx2; drug sensitization; proteoglycan; immune checkpoint inhibitor; high throughput sequencing; combination drug therapy; estrogen receptor positive breast cancer; acyltransferase inhibitor; human epidermal growth factor receptor 2 positive breast cancer; enzalutamide; programmed death 1 receptor blocking agent; humans; human; female; article; cyclin dependent kinase 4 inhibitor; alpelisib; estrogen receptor negative breast cancer; oncogenomics; early cancer diagnosis; antigestagen; antibody drug conjugate; cyclin dependent kinase 6 inhibitor; breast radiotherapy; esr1 gene; propionic acid; ductal breast carcinoma in situ; invasive lobular breast carcinoma; estrogen receptor-positive, her2-negative breast cancer; proapoptotic activity; invasive ductal breast carcinoma; chitinase 3 like protein 1; cell stemness; inavolisib; international symposium; osteomodulin; r 1d 2 10; rac1 protein inhibitor; rly 2608; tersolisib |
| Journal Title: | Medicina (Buenos Aires) |
| Volume: | 85 |
| Issue: | 3 |
| ISSN: | 00257680 |
| Publisher: | Unknown |
| Date Published: | 2025-01-01 |
| Start Page: | 586 |
| End Page: | 596 |
| Language: | English |
| PUBMED: | 40577145 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
